Amron Arthur H 4

What Happened

• Arthur H. Amron, a director of NEPHROS, received 3,574 shares on 2026-05-11 as an award/compensation (reported as transaction code A). The shares were issued in lieu of cash fees; price reported $0.00, so the Form 4 shows $0.00 total value for this acquisition. This is not a purchase or sale by the insider but a compensation issuance.

Key Details

• Transaction date: 2026-05-11; Form 4 filed: 2026-06-12 (filed ~32 days after the transaction).
• Considered an award/compensation (code A); acquisition recorded at $0.00 per share.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnote F1: shares issued in lieu of cash fees for board service.
• Footnotes F2 & F3: describe vesting schedules for related/options awards (2,441-share tranches vesting 5/14/24, 5/14/25, 5/14/26; and 2,350-share tranches vesting 1/1/25, 1/1/26, 1/1/27).
• Filing timeliness: the Form 4 was filed late relative to the reported transaction date (SEC Form 4s are generally due within 2 business days), which may be a compliance note for investors.

Context

• Shares issued in lieu of cash are a compensation event and do not necessarily indicate the insider is buying or selling stock; they reflect board pay being delivered in equity.
• Footnotes indicate outstanding option/award vesting schedules that affect future potential acquisitions but do not change that this specific transaction was a cash-in-lieu equity grant.